• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next

    Simply Wall St·08/08/2026 08:29:14
    Listen to the news
    • In the past week, ImmunityBio, Inc. reported second-quarter 2026 results showing revenue of US$51.24 million versus US$26.43 million a year earlier, alongside a wider net loss of US$230.38 million and basic loss per share from continuing operations of US$0.22, up from US$0.10.
    • A few days earlier, the company received broad UAE marketing authorization for its immunotherapy ANKTIVA across bladder and lung cancer indications, expanding its regulatory footprint to 34 countries and highlighting the contrast between growing commercial reach and very large ongoing losses.
    • Next, we’ll examine how ANKTIVA’s expanded UAE approvals across bladder and lung cancer could reshape ImmunityBio’s investment narrative and future expectations.

    Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

    ImmunityBio Investment Narrative Recap

    To own ImmunityBio, you need to believe ANKTIVA can grow from a single core product into a broader oncology platform while the company absorbs very large ongoing losses. The UAE approvals and stronger revenue do not change the key short term focus, which remains regulatory progress for additional bladder cancer uses and the risk that expanding trials and commercialization keep net losses elevated for longer than some investors may expect.

    The UAE decision to authorize ANKTIVA for both BCG unresponsive non muscle invasive bladder cancer and metastatic non small cell lung cancer is the most relevant development here. It extends the drug’s reach to 34 countries, building on earlier Saudi approvals and giving more real world context for how quickly new markets might contribute, and how that interacts with the existing catalyst around future label expansions in bladder cancer.

    Yet in contrast to the recent approvals, investors should still be aware that sustained heavy losses and dependence on ANKTIVA...

    Read the full narrative on ImmunityBio (it's free!)

    ImmunityBio's narrative projects $1.6 billion revenue and $673.2 million earnings by 2029. This requires 125.9% yearly revenue growth and about a $1.53 billion earnings increase from -$854.5 million today.

    Uncover how ImmunityBio's forecasts yield a $13.00 fair value, a 70% upside to its current price.

    Exploring Other Perspectives

    IBRX 1-Year Stock Price Chart
    IBRX 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already assuming about US$1.7 billion in 2029 revenue and US$719.9 million in earnings, yet they still warned that reliance on ANKTIVA and country by country approvals in lung cancer could limit upside; the new UAE authorization might eventually shift those views, but you should recognize how far apart expectations can be before deciding which narrative you find more realistic.

    Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth over 6x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.